

Amendment to the Specification

Please amend the title of the invention as follows:

Antibodies to Human Tumor Necrosis Factor Receptor TR9

Please amend the first full paragraph on page 1 as follows:

This application is a divisional of copending U.S. Patent Application Serial No. 09/527,236, filed March 16, 2000 (now United States Patent No. 6,358,508), which, in turn, is a continuation-in-part of copending U.S. Application Serial No. 09/095,094, filed June 10, 1998, which, in turn, claims benefit under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/052,991, filed June 11, 1997, and further claims benefit of priority under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/126,019, filed on March 24, 1999 and U.S. Provisional Application Serial No. 60/134,220, filed on May 14, 1999; each of which is hereby incorporated by reference in its entirety.

Please amend the abstract of the disclosure as follows:

The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies, vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.